MedinCell S.A.
PAR: MEDCL.PA0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Euronext Paris
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Christophe Douat
- Employees
- 131
- Headquarters
- Jacou, France
- IPO year
- 2018
- Market cap
- €941.5M
- Website
- https://www.medincell.com
Loading MEDCL…
Loading profile data…Frequently asked questions about MEDCL
What does MedinCell S.A. (MEDCL.PA) do?
MedinCell S.A. develops various therapeutic solutions. It develops solutions based on BEPO, a technology for long-acting injectable products based on proprietary copolymers and a biocompatible solvent, which solubilizes or suspends the active pharmaceutical ingredients. The company's products in development include mdc-IRM, a subcutaneous inject...
Where does MEDCL.PA trade?
MedinCell S.A. (MEDCL.PA) trades on the Euronext Paris.
What sector is MEDCL.PA in?
MedinCell S.A. (MEDCL.PA) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of MedinCell S.A.?
Christophe Douat is the chief executive officer of MedinCell S.A. (MEDCL.PA).
Where is MedinCell S.A. headquartered?
MedinCell S.A. is headquartered in France.
Does MEDCL.PA pay a dividend?
MedinCell S.A. (MEDCL.PA) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did MEDCL.PA go public?
MedinCell S.A. (MEDCL.PA) completed its initial public offering in 2018.